#1PESA |ORGANIGRAM INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) Q1 Fiscal 2024 12 | 31 | 23 1#2CAUTIONARY STATEMENT This document is current as of December 31, 2023, except where otherwise stated. The infomation contained in this presentation is provided by Organigram Holdings Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation there to. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada or the United States has reviewed this presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation is not meant to provide a complete or comprehensive analysis of Organigram's financial or business prospects. To the maximum extent pemitted by law, none of Organigram nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. This presentation contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors. that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, perfomance or achievements expressed or implied by the forward-looking information contained in this presentation. Risks, uncertainties and other factors involved with forward looking information could cause actual events, results, perfomance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company's most recent annual information fom, ORGANIGRAM management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.com) and filed or fumished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Although the Company believes that the assumptions and factors used in preparing the forward-looking infomation in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this presentation is made as of the date of this presentation and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking in formation, whether as a result of new infomation, future events or otherwise. The descriptions of the tems of the agreements referenced in this release are qualified by the terms of the agreements themselves, copies of which shall be filed under Organigram's profile on SEDAR+ (see www.sedarplus.com) and filed or fumished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). The financial information in this document contains certain financial performance measures that are not defined by and do not have any standardized meaning under IFRS and are used by management to assess the financial and operation al perfomance of the Company. These include adjusted EBITDA and adju ste d gross margin (adjusted gross margin %). The Company believes that the se non- IFRS financial measures, addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company's operating results, underlying perfomance and prospects in a similar manner to the Company's management. As there are no standardized methods of calculating the se non-IFRS measures, the Company's approach may differ from those used by other issuers, and accordingly, the use of these measures may not be directly comparable. Accordingly, the se non-IFRS measures are intended to provide additional infomation and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For further information regarding the se non-IFRS measures, including definitions, and a quantitative reconciliation to the most directly comparable IFRS measure, see the information under the heading "Cautionary Statement Regarding Certain Non- IFRS Measures" and the reconciliation to IFRS measures under the heading "Financial Results and Review of Operations" in the Company's management discussion and analysis of financial conditions and results of operations for the three months ended December 31, 2023 and November 30, 2022 (the "Q1 Fiscal 2024 MD&A") incorporated by reference in this presentation and filed under Organigram's profile of SEDAR+ (see www.sedarplus.com) and filed or fumished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act") ("U.S. Person"), or in any other jurisdiction in which such an offer would be illegal. Organigram's shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disse m in a ted or transmitted in to any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws. This investor presentation contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently im precise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein. 2#3WHO WE ARE Founded in 2013, we are an award-winning cannabis licensed producer with operations spread across Canada © Our Vision: To be a respected global leader in the emerging cannabis movement Our Mission: To delight consumers with trusted brands that deliver innovative cannabis products and experiences while promoting education and industry advocacy ORGANIGRAM Licensed Producer of the Year 2022 KING magazine SHREDY RIP-STRIP HASH SHRED RIP-STRIP HASH blueberry blaster swee SHREDX RIP-STRIP HASH tropic thunder WINNER KING Innovation of the Year Award! KING magazine EDISON JOLTS ARCTIC CHERRY SATIVA LOZENGES 100% ste EDISON JOLTS FRESHLY MINTED SATIVA LOZENGES 100 MOST INNOVATIVE PRODUCT OF THE YEAR KING KING AWARDS 2023 INNOVATION OF THE YEAR *** 3033 SHRED Rip Strips 2022 EDISON JOLTS ELECTRIC LEMON SATIVA LOZENGES 100 EDISON JOLTS. 2023 ORGANIGRAM 3#4OUR STRATEGY INNOVATION CONSUMER FOCUS ORGANIGRAM EFFICIENCY Leverage our brands, product portfolio and culture of innovation to: Reach Increase market share new markets Drive profitability EXPANSION Deliver long-term shareholder value 4#5NEAR-TERM STRATEGY Organigram continues to demonstrate a track record of innovation informed by consumer research, resulting in market share increases in several categories INNOVATION ORGANIGRAM ● Pink yuzu gummies - 2:1 THC:THCV Guava Lime Go-Time Heavies THCV milled flower Launched revolutionary vape hardware to address growth in the category Expanding into familiar formats with tube-style pre-rolls Planning launch of nano-emulsion gummies with clinically studied benefits Leverage our brands, product portfolio and culture of innovation to: Increase market share CONSUMER FOCUS ● ● Revolutionized hash with patent pending SHRED X Rip-Strips First to market with ingestible extracts and milled flower Introduced whole-flower derived THCV products to the Canadian consumer ● ● ● ● ● Drive profitability 5#6LONG-TERM STRATEGY Organigram has strategically deployed capital to fuel automation, production efficiency, and product consistency needed to attract and retain international distribution partners ● ● ● ● Production and packaging lines for gummies, milled flower, and pre-rolls are now highly automated Conversion of portion of grow rooms to seed-based production in F2024 drives product consistency and further cost savings $124.6M follow-on investment from BAT to fund international and strategic growth initiatives² $18.9M in international sales in F2023 (Australia & Israel). German shipments commenced in January 2024, and UK shipments expected to commence within the coming months. 1. British American Tobacco p.l.c., ("BAT") strategic investor in Organigram. 2. Announced on November 6, 2023. Leverage our brands, product portfolio and culture of innovation to: ORGANIGRAM EFFICIENCY Deliver long-term shareholder value EXPANSION Reach new markets 6#7ESTABLISHED TREND OF REVENUE GROWTH ORGANIGRAM Annual Revenue $ millions $80.4 $97.5 F2019 $86.7 $103.3 F2020 $79.1 $109.8 F2021 Net Revenue Gross Revenue $145.8 $209.1 F2022 $161.6 $233.6 F2023 ¹ 1 1. F2023 represents 13 months due to a change in Organigram's year end. 7#8● ● ORGANIGRAM KEY STRENGTHS STRONG BALANCE SHEET Negligible debt (less than $0.2M) $54.6M in cash¹ Balance sheet to be further strengthened by $124.6M follow- on commitment from BAT announced Nov ember 6, 2023 ORGANIGRAM ● ● STATE-OF-THE- ART FACILITIES *** Moncton facility is one of the largest indoor cannabis facility in the world Centre of Excellence, an R&D collaboration in partnership with BAT Dedicated edibles facility in Winnipeg, MB • Craft cultivation and hash facility in Lac- Supérieur, QB ● ● ● ● HIGH PERFORMING $233.6M gross revenue in FY2023 #2 in national market share² #1 market share in milled flower and hash² #2 market share in gummies ² #3 market share in pre-rolls and flower² ● NATIONAL & INTERNATIONAL REACH 1. Including restricted cash as of December 31, 2023. 2. As of December 31, 2023 - Multiple Sources (Hify re, Weedcrawler, provincial boards, internal modelling). National sales and distribution in all 10 Canadian provinces and the Yukon Serving international markets via export perm its • Creation of project Jupiter - an $83 million strategic investment pool focused on international markets ● ● ● ● INNOVATION FOCUS First to market with multiple award- winning innovative form ats PDC with BAT for long term research and IP Launched exclusive new vape hardware in Q2 F2024 Invested in seed- based production and in biosynthesis ● ● EXCELLENCE IN EXECUTION Consumer insights - focused leading to brand & product excellence Track record of successful post-M&A integrations Responsible capital stewardship resulting in flexibility in tough market conditions 8#9BAT INVESTMENTS IN ORGANIGRAM March 2021 - $221 million strategic investment from subsidiary of BAT for 19.9% equity interest in Organigram Product Development Collaboration (PDC) with formation of a Center of Excellence (CoE) at our Moncton campus Focused on developing the next generation of cannabis products, IP and technologies ● ● November 2023- $124.6 million follow-on investment from subsidiary of BAT in three equal tranches between January 2024 and February 2025 for: 45.0% economic interest in Organigram (accreting to maximum ● of 49.0%), voting interest capped at 30.0% with maximum 30.0% Board rights Private placement at C$3.2203/share2 yielding $124.6 million Organigram to create a Strategic Investment Pool named Jupiter, to be funded with C$83.1 million over the course of the three tranches of the investment • Jupiter will target investments in emerging cannabis opportunities that enable Organigram to apply industry-leading capabilities ● ● ● ● to new markets, thus expanding its global footprint $41.5 million proceeds for general corporate purposes First $41.5 million tranche closed in January 2024 1. Calculated on a non-diluted basis. 2. On the last trading day pre-announcement (November 3, 2023) of the transaction. Organigram shares closed at C$1.59/share on the Toronto Stock Exchange. ORGANIGRAM ORGANIGRAM BAT 9#10Collaboration Highlights Since March 2021, following a C$221 million strategic investment from BAT subsidiary, the partnership has gone from strength-to-streng th ● ● ● PRODUCT DEVELOPMENT COLLABORATION Organigram and BAT contributing complimentary capabilities and sharing a commitment to responsible category stewardship. The PDC continues to focus on the development of next generation products, adhering to the highest regulatory and compliance standards ● Significant achievements have materialized from a scientific development standpoint in terms of revenue driving product capability Organigram has benefitted from BAT's deep understanding of plant science and device and product technology BAT has gained substantial knowledge from Organigram with respect to the cannabis plant and product category The PDC is in late-stage development of a suite of emulsions, novel vapour formulations, flavour innovations, and packaging solutions which are to be applied across some products in Organigram's portfolio in calendar year 2024 For ingestible innovations, Organigram has completed pharmacokinetic (PK) studies to substantiate benefits of emulsification technologies and analysis of results is underway ORGANIGRAM BAT "PDC" A BETTER TOMORROW ORGANIGRAM Dedication to Research and Product Development 10#11JUPITER INVESTMENT APPROACH Jupiter will target investments in emerging cannabis opportunities 1 ● ● ● All potential investments will be made against Organigram's strategic vision for the future, focusing on long-term sustainable growth and global cannabis. leadership Targeting investments that will enable Organigram to apply its industry- leading capabilities to new markets Jupiter to be set-up and managed by an internal team at Organigram Internal team will be focused on sourcing future investments, enabling both an entrepreneurial approach and application of best-in-class knowledge All investments will go through legal due diligence, ensuring compliance with both applicable laws and Organigram's listings on the NASDAQ & TSX ORGANIGRAM Geographies USA Emerging global markets 3 ● Sectors Adult-use THC Hemp-derived CBD/CBD+ (minor cannabinoids) CPG Cannabis ancillary Priority Investment Pillars 2 Categories & Tech Non-combustible ● ● ● inhalation Edibles Beverages Novel IP & devices 4 Value Chain Segments Genetics Product development Brand ● ● ● 11#12● ● ● ● STRATEGIC INVESTMENTS IN INNOVATION Organigram has a track-record of first-to-market innovations and is positioned to realize defensible competitive advantages from investments in technology First-to-market Successes Milled flower with custom flavour blends introduced under Organigram's highly successful SHRED brand Patent pending Rip-Strip hash - a revolutionary new way for consumers to experience Hash Edison JOLTS - the first patented ingestible extract introduced to the Canadian consumer Canada's only whole-flower derived THCV portfolio - THCV is a minor cannabinoid to uted for its appetite suppressing qualities SHREDEMS GUAVA LIME GO-TIME ng THC 10 mg THCV PER PACK LATIVA GUAM ORGANIGRAM EDISON JOLTS ELECTRIC LEMON SATIVA LOZENGES 100 EDISON JOLTS FRESHLY MINTED SATIVA LOZENGES 00 SHREDY RIP-STRIP HASH 10 STRIPS | 2g 35%+THC blueberry blaster THE nder ● ● ● ● Growing Portfolio of Competitive Technologies The PDC is in the late-stage development of product innovations which are planned to be applied to certain products within Organigram's portfolio in calendar 2024 Organigram's facility CAPEX projects focused on production & packaging automation and internalizing testing & remediation are complete and expect to realize annual cost savings in F2024 Investment in Green Tank Technologies Corp. ("Greentank") vaporization hardware to solve pain points in flavour performance and clogging Investment in US-based Phylos Bioscience Inc. ("Phylos") provides exclusive access to high-THCV cultivars and technical know-how. As a result, Organigram has begun transitioning a portion of its grow rooms to cost-effective, seed-based production, and this is expected to yield more robust and consistent harvests while reducing grow time and production costs 12#13● DOMESTIC & INTERNATIONAL EXPANSION Organigram continues to grow domestic market share in key categories and over-indexes in international sales as a proportion of Canadian exports: Canadian Market #2 market share position in Canada¹ #2 market share in gummies¹ #1 market share in milled flower and hash¹ #1 market share in the Maritimes, and #3 in Ontario and Quebec, two of Canada's largest markets ¹ Expanding market share in the rapidly growing pre-roll category after recent highly successful launches of tube-style pre-rolls and diamond + distillate infused-pre-rolls, resulting in claiming the #3 position in the overall pre-roll category¹ ORGANIGRAM ● ● Rest of World In F2023 Organigram shipped an estimated 10% of all exported product from Canada² to international markets. (including Israel and Australia) New supply agreements signed with Sanity Group GmbH ("Sanity Group") in Germany and 4C Labs Ltd. in the UK expected to bolster international sales in Fiscal 2024 - First flower shipped to Germany in Q1 F2024 In F2023 Organigram shipped C$18.9 million in flower vs. C$15.1 million in F2022 ✡ 1.As of December 31, 2023 - multiple sources (Hify re, Weedcrawler, provincial boards, internal modelling). 2. Measured by dollar value and sourced from BDSA, available Statistics Canada data & internal shipped sales data. * 13#14STATE OF THE ART FACILITIES Organigram's legacy of execution excellence & stability is established in the Canadian market, supported by three fully-scaled, state-of-the-art facilities: Moncton One of the largest indoor cannabis facilities in the world ~85,000 kg/year of low-cost, high-quality indoor flower Over 130, three-tiered, modular, strain- specific grow rooms provide the ability to control critical environmental requirements per strain 11 additional plant science rooms for testing prior to commercial launch Utilizes low-cost, high-yielding, LED lighting Home to the BAT-Organigram joint R&D Center of Excellence 57 KEL Winnipeg 51,000 sq. ft. edibles facility with automated cutting-edge equipment capable of producing up to 4 million gummies monthly Designed to produce nutraceutical-grade cannabis edibles including pectin, gelatin, and sugar-free soft chews, toffee, and caramel with novel capabilities ● ● Lac-Supérieur Producing hang-dried, hand-trimmed, artisanal craft cannabis and premium Afghan-style hash Hash production capacity of 2 million units per year Greenhouse expansion from 600kg/yr to 2,400kg/yr of craft flower recently completed with first harvest completed in December 2023#15BRAND PORTFOLIO 15#16WELL-ROUNDED BRAND PORTFOLIO Pricing $ Segment Available Planned Formats Tangible Brand Attributes BIG BAG O' BUDS Super Value Whole Flower Strain Specific Flower High Quality Genetics Good value ORGANIGRAM HOLY MOUNTAIN SHRED Value Whole Flower Pressed Hash Iconic Strains High Potency Products Killer Prices Value Pre-Milled Flower, Pre-Roll Joints, Infused Gummies, 510 Vape Carts, Rip-Strip Hash & Infused Pre-Rolls Good THC Potency Great Value Big Flavour monjour Mainstream CBD & Minor Cannabinoid Gum mies Assorted Flavours Vegan & Sugar-free Offerings Trailblazer EDISON CANNABIS CO Mainstream Pre-Rolls, Infused Pre-Rolls, THC & Minor Cannabinoid Gum mies Assorted Flavours Vegan & Sugar-free Offerings Mainstream Whole Flower, Pre-Roll Joints & Lozenges Potent & Flavourful Strains Unparalleled Genetics Strain Specific Grow Rooms FLEUR ARTISANALE TREMBLANT LAURENTIAN THE ART OF HASH L'ART DU HASCHISH Premium Hashish, Hash Infused Pre-rolls & Pre-rolls Authentic Recipes High Potency Hash CRAFT FLOWER Craft Whole Flower Pre-Roll Joints Hand Trim med Hand Packed Hang Dried 16#17● ● DYNAMIC BRAND PERFORMANCE NEW RIP-STRIP HASH JUST RRRRIP IT! RIP IT P-STRIP HASH tropic thunder ORGANIGRAM 35%* THC Terp-infused Hash for Weed Fans 2g 10 HASH STRIPS STRIP IT 3 SALON Launched in March 2023 Rip-Strip Hash on a Tear GO! Over 330K units shipped approaching $9.9 million in retail sales as of January 31st, 20241 ● VEGAN CBD monjour BERRY GOOD DAY Monjour Market Share Up by 14.3% MS Points vs. Prior Year¹ Monjour Holds 62% of the pure- CBD national market share as of Q1 20241 TREMBLANT AFGHAN BLACK HASH THC 35-438 Organigram is the #1 LP in Concentrates Organigram holds >21% of national market share in Hash as of fiscal Q1, 20241 1.As of February 6, 2024 - Multiple Sources (Hify re, Weedcrawler, provincial boards, internal modelling). 17#18DYNAMIC BRAND PERFORMANCE ULTRA HEAVY 40%+ THC ORGANIGRAM HEAVIES Not for Lightweights. HEAVIES SHRED SHRED X Heavies - 40%+ THC Infused Pre-Rolls (IPRS) IPR's are the biggest contributor for growth in Canada (40% of overall growth came from IPRS) 1 As of L4W January 31, 2024, Organigram is #2 in infused pre-rolls 1 LAB 2002 200 MOD 201 HOLY MOUNTAIN HOLY SMOKES 10 x 0.4G TUBE STYLE PRE-ROLL HOL 20 20%+ THC HOLY SMOKES ONE SLIM ROLL TO RULE THEM ALL ASK YOUR BUDTENDER! Tube Style Pre-Rolls Tube style pre roll segment growing at 52% year- over-year versus cones at 0.8% (Q1 vs LY) ¹ Organigram market share in tube-style pre-rolls is 15.7% in L4W as of January 31, 20241 1.As of February 6, 2024 - Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling). 18#19STRATEGIC INVESTMENTS 19#20INVESTMENT IN DISRUPTIVE SHREDX VAPING TECHNOLOGY ● In March of 2023, Organigram invested C$5.5M into Greentank, a vape R&D firm and hardware manufacturer ● Greentank's heating technology is the first meaningful innovation in the vape space in almost a decade. • Invented a novel heating element which replaces ceramic which will produce more consistent flavour, reduce clogging and produce smaller particle size which may increase potency With an 18-month exclusivity period, it will transform Organigram's vape hardware line-up and enhance market position. • Commercialization began in Q2 F2024 ORGANIGRAM ALIME GO SHREDX NER PUCKER P SHREDY GRAPPLE JUIC FRESHER FLAVOUR First-Puff flavour from start to finish (no ceramic burnt oil taste!) COLDER VAPOUR 50% colder vapour* vs. leading ceramic based heating technology DEEPER HITS Smaller vapour particles for smoother, deeper tokes QUANTUM LONGER BATTERY LIFE Less vapourizing power required = 30% longer battery life* VAPE *Based on initial lab testing vs. leading ceramic based heating technology ------ ‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒#21INVESTMENT IN SEED GENETICS & THCV ● In May of 2023, Organigram made its first investment into the U.S cannabis market by issuing a strategic convertible loan to Phylos ● ● ● Phylos will enable Organigram to accelerate the launch of products containing THCV in the Canadian market - THCV provides consumer with a differentiated experience compared to THC (appetite suppression, no cognitive impairment, energizing and focusing effect) Organigram will significantly reduce operating costs by transitioning its flower production from cloning to seed which reduces the need for cloning, propagation, and pre-vegetation Seed-based cultivation using "F1" seeds produces more robust and consistent plants, yielding consistent cannabinoid and terpene profiles, uniform size, and other desirous qualities. In Q1 F2024, due to the achievement of THCV concentration and aroma specific milestones from F1 seeds, Organigram advanced the second tranche of US$2.75 million to Phylos for a total current investment of US $6.0 million in senior secured convertible loans First seed-based room planted in Q1 F2024 to begin transition of a portion of Moncton facility to growing from more cost-effective and consistent F1 seeds ORGANIGRAM Po phylos 238 18.5-#22INVESTMENT IN DISRUPTIVE TECHNOLOGY-BIOSYNTHESIS ● 49% ownership (if convertible debt converted) of Hyasynth Biologicals Inc., a pioneer in cannabinoid science - supply agreement in place • Biosynthesis process uses patent-pending yeast strains and enzymes to produce pure cannabinoids (not synthetic) without growing cannabis plants Potential to create a scalable supply of pure cannabinoids at a fraction of the cost and time of traditional cultivation using smaller environmental footprint ORGANIGRAM BIOSYNTHESIS A proprietary cannabinoid manufacturing system that can product rare cannabinoids. 1 hyasynth How it works? Biosynthesis can be used to produce cannabinoids that are identical to those produced by the plant itself. 3 Genome engineering of yeast: A group of genes for cannabinoid production are added to the yeast genome of a yeast strain, where it provides instructions to produce cannabinoid compounds. Yeast fermentation and purification: New yeast strains are grown in fermentation over a few days and pure cannabinoids are extracted at the end of the process. 2 The process is conducted at large scale, resulting in pure cannabinoids that can be used as ingredients in other products.#23INTERNATIONAL 23#24SIGNIFICANT INTERNATIONAL SALES GROWTH INTERNATIONAL NET REVENUE 1 $ millions High margin international sales expected to increase further in F2024 1. International shipments do not attract Canadian Federal excise taxes and therefore gross, and net revenues are equal. 2. F2023 represents 13 months due to a change in Organigram's year end. ORGANIGRAM $3.8 Cumulative Pre-F2022 $15.1 F2022 $18.9 F2023 2 24#25INTERNATIONAL BUSINESS In F2023 shipped $18.9 million in flower vs. $15.1 million in full year F2022 • In Q1 F2024, Organigram shipped $1 million in flower to Australia • May 22, 2023: announced a new agreement to supply the German medical market through Sanity Group • January 2024: Firstshipment of flower sent to Sanity Group in Germany August 15, 2023: announced a new supply agreement with 4C Labs to supply medical cannabis to UK market with first shipment expected in the coming months ● Activities are subject to compliance with all applicable laws, including receipt of all requisite approvals from Health Canada, the Israeli Ministry of Health, and any other applicable regulatory authorities and changing regulatory landscape. ORGANIGRAM Sanity Group CANNDOC CANNATREK™ From seed to patient. MEDCAN 4C LABS AUSTRALIA#26QUARTERLY UPDATES & HIGHLIGHTS Q1 F2024 26#27● A LEADING CANADIAN LP Organigram achieved the #2 national market share position¹ • Held the #1 position in milled flower, the #1 position in concentrates, the #2 position in gummies, and the #3 position in all pre-rolls nationally¹ • Reintroduced Edison Jolts to market, achieving #2 brand position in capsules and ingestible extracts category in December 2023¹ • #1 in LP in Atlantic Canada, #2 in Ontario, and held top 5 market position in rest of Canada¹ 1. As of December 31, 2023 - Multiple Sources (Hify re, Weedcrawler, provincial boards, internal modelling). ORGANIGRAM * THC TREMBLAN RIP-STRIP HASH 10 STRIPS | 29 | 35 % + THC blueberry blaster THC SHREDENS WILD BERRY BLAZE RAIES SAUVAGES ECLATANTES monjour BERRY GOOD DAY PETITS FRUITS DU JOUR GAMES/30 JUUBES CED C80/Total CBD Total: 600 mg THC/Total THC Total: 1.35 mp CD Tetal per unkipar unit 20 mg per anar unité: 4.05 m CTTHCT WARNING THC can c Dalyarnes bring an ar MISE EN G camabis co sarti mentale a quddieme augmenta lep Duagyar dobles SHRED TROPIC THUNDER TROPIC THUNDER LEND MELANGE SELECTIONNE HOLY MOUNTAIN XXL 27#28QUARTERLY REVENUE REVENUE $ millions ORGANIGRAM $31.8 $43.9 Q2 F22 $38.1 $55.2 Q3 F22 $45.5 $65.7 Q4 F22 $43.3 $60.9 Q1 F23 Net Revenue $39.5 $52.9 Q2 F23 Gross Revenue $32.8 1. Q4 F23 represents a 4-month period due to a change in Organigram's year end. Net and gross revenue here have been normalized to reflect a 3-month period. $48.4 Q3 F23 $34.5 $53.6 Q4 F23 1 $36.5 $56.3 Q1 F24 28#29ADJUSTED GROSS MARGIN ADJUSTED GROSS MARGIN¹ $ millions and % of Net Revenue 1. Adjusted gross margin is a non-IFRS financial measure not defined under IFRS and which does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q1 Fiscal 2024 MD&A for definitions and a reconciliation to IFRS ORGANIGRAM $8.2 26% Q2 F22 $9.3 24% Q3 F22 $10.4 23% Q4 F22 $12.8 30% Q1 F23 $13.4 34% Q2 F23 2. Q4 F'23 represents a 4-month period due to a change in Organigram's year end. Adjusted gross margin dollars here have been normalized to reflect a 3-month period. $6.1 19% Q3 F23 $5.9 17% Q4 F23 2 $11.2 31% Q1 F24#301. ADJUSTED EBITDA Adjusted EBITDA is a non-IFRS Financial Measure not defined by and does not have. any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q1 Fiscal 2024 MD&A for definitions and a reconciliation to IFRS. ORGANIGRAM ADJUSTED EBITDA¹ $ millions $1.6 Q2 F22 $0.6 Q3 F22 $5.6 $3.2 ill Q4 F22 $5.6 Q1 F23 Q2 F23 -$2.9 1. Q4 F2023 represents 4 months due to a change in Organigram's year end. Adjusted EBITDA here has been normalized to reflect a 3- month period. Q3 F23 -$1.8 Q4 F23² $0.1 Q1 F24#31● 01 F2024 STRATEGIC HIGHLIGHTS Completed planting first seed-based production grow room resulting from strategic investment in US-based Phylos • Advanced the second tranche of US$2.75 million to Phylos for a total current investment of US$6.0 million in senior secured convertible loans due to early achievement of THCV concentration and aroma milestones for F1 seeds • Completed first craft harvest resulting from the completed expansion of the Company's Lac-Supérieur facility • Product Development Collaboration with BAT moving rapidly toward product commercialization. PK study for nano-emulsion gummy technology complete and the Company is compiling and analyzing results to substantiate product claims. regarding onset and half-life • Applied for EU-GMP certification of Moncton facility in November 2023 and awaiting audit • Subsequent to Q1 F2024 announced shareholder approval and closing of first $41.5 million tranche of $124.6 million follow-on investment from BAT and creation of the Jupiter investment pool to increase Organigram's international footprint ORGANIGRAM BAT A BETTER TOMORROW afo PHYLOS BIOSCIENCE GREENTANK#3201 F2024 KEY EFFICIENCY HIGHLIGHTS Moncton ● ● ● ● Lac-Supérieur Construction complete with second ultrasonic knife added to meet strong demand for Rip-Strip Hash while lowering labour costs Greenhouse expanded to 2400 kg/year - first harvest completed in December 2023 ● ● Harvest of 19,860 kg in Q1 F2024 Increasing efficiency through internalizing testing and remediation, as well as increasing automation - $2.1 M in savings realized in Q1 F2024 53% increase in flower produced with over 24% THC content Cantos machine pre-roll production run rate improved by 38% CME pre-roll packaging machine improved throughput by 100% SHRED Heavies production rate improved 150% PDC & Center of Excellence For ingestible innovations, Organigram has completed pharmacokinetic (PK) studies to substantiate benefits of emulsification technologies and analysis of results is underway ● ORGANIGRAM EFFICIENCY#33STRONG BALANCE SHEET AND LIQUIDITY ● ● ● On December 31, 2023, the Company had cash of $54.6 million (including restricted cash) In Q1 F2024, Organigram generated $7.7 million in cash flow from operations In January 2024, the Company closed the first $41.5 million tranche of $124.6 million follow-on investment from BAT Negligible debt (less than $0.2 million) ORGANIGRAM * THC TREMBLANT SHREDY RIP-STRIP HASH 10 STRIPS | 29 | 35% + THC 571 blueberry blaster SHREDENS WILD BERRY BLAZE ES SAUVAGES ECLATANTES PLAY 4 and pralanga ngana w wigeum Ling La consortation tipas proko per des prob buca e que THC KRUNING E pa monjour HOLY MOUNTAIN SHRED TROPIC THUNDER BERRY GOOD DAY PETITS FRUITS DU JOUR und WARNING: Frequent and pr THC can contribute to me Daly or near-daily use bring on or worsen doord MISE EN GARDE: La c cannabis contenant de T santé mentale aud quotideme augmente le c ou aggraver des troubles